Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin with chemotherapy in pediatric untreated FLT3-mutated AML
2017-004830-28Phase 2Active
- Sponsor
- Novartis
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midostaurin in acute myeloid leukemia (AML), sponsored by Novartis. Primary endpoint: Dose-limiting toxicity (DLT) and safety in Part 1 dose-determining set. Started Aug 2018; status: active.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2017-004830-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004830-28.